Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Astellas, Daiichi Sankyo Form Compound Library Sharing Program

March 19, 2014 1:21 am | by Daiichi Sankyo | News | Comments

Astellas Pharma and Daiichi Sankyo announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds. This is the first time that a compound library partnership of this scale has been formed in Japan. Read more...


New Therapeutic Target Discovered for Alzheimer’s

March 18, 2014 3:09 pm | News | Comments

A team of scientists is reporting that cathepsin B gene knockout or its reduction by an enzyme inhibitor blocks creation of key neurotoxic pGlu-A-beta peptides linked to Alzheimer’s disease. Read more...              


Scientists Slow Development of Cell-Killing Alzheimer's Plaques

March 18, 2014 2:58 pm | News | Comments

Researchers have learned how to fix a cellular structure called the Golgi that mysteriously becomes fragmented in all Alzheimer's patients and appears to be a major cause of the disease. Read more...               


Dog DNA Plays Role in Developing New Human Therapies

March 18, 2014 2:35 pm | News | Comments

Using genomic analysis to study cancer in dogs can help develop new therapies for humans with cancer, according to a new proof-of-concept study. Read more...                           


An End to Animal Testing for Drug Discovery?

March 18, 2014 2:15 pm | News | Comments

As some countries and companies roll out new rules to limit animal testing in pharmaceutical products designed for people, scientists are stepping in with a new way to test therapeutic drug candidates and determine drug safety and drug interactions— without using animals. Read more...


FDA Delays Biogen Idec MS Drug Decision

March 18, 2014 2:02 pm | News | Comments

Biogen Idec announced that the FDA has extended the initial Prescription Drug User Fee Act date for its review of the BLA for marketing approval of Plegridy, a possible treatment for relapsing forms of multiple sclerosis. Read more...     


Centrifuge Delivers High-Performance, High-Volume Batch Bioprocessing

March 18, 2014 11:12 am | Thermo Fisher Scientific | Product Releases | Comments

The new Thermo Scientific Sorvall RC BIOS 10 large capacity centrifuge system is designed to improve productivity and ensure sample safety and integrity and is ideal for a range of cell culture and bioprocessing applications.

SillaJen Completes Jennerex Acquisition

March 18, 2014 11:00 am | News | Comments

SillaJen Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, announced that it had completed the acquisition of San Francisco-based Jennerex Inc. Read more...   


Celgene's Abraxane Approved for Pancreatic Cancer in Australia

March 18, 2014 10:53 am | News | Comments

Australian biopharmaceutical company Specialized Therapeutics Australia announced that Abraxane, in combination with gemcitabine, is now approved by Australia's Therapeutic Goods Administration for the treatment of metastatic pancreatic cancer. Read more...


Amgen Drug Hits Endpoint of Cholesterol Reduction

March 18, 2014 10:44 am | News | Comments

Amgen announced that the Phase 3 TESLA trial evaluating evolocumab met its primary endpoint of the percent reduction from baseline at week 12 in low-density lipoprotein cholesterol (LDL-C). Read more...              


FDA OKs Phase 2 Trial in Orphan Mitochondrial Disease

March 18, 2014 10:38 am | News | Comments

Edison Pharmaceuticals announced that the company's Investigative New Drug (IND) application to initiate "A Phase 2 Safety and Efficacy Study of EPI-743 (Vincerinone) in Children with Pearson Syndrome," was approved by the FDA. Read more... 


New Imaging Approach Speeds Prostate Cancer Drug Testing

March 18, 2014 10:26 am | News | Comments

Scientists have developed a new way to test the effectiveness of a drug for prostate cancer that has spread to the bone, which is currently incurable, according to new research. Read more...                 


Astellas, Medivation Want New Cancer Indication for Xtandi

March 18, 2014 8:22 am | News | Comments

Astellas Pharma and Medivation announced the submission of a supplemental New Drug Application to the FDA seeking approval of Xtandi capsules for the treatment of men with metastatic castration-resistant prostate cancer who have not received chemotherapy. Read more...


AstraZeneca Makes Progress on Global Brilinta Trial

March 17, 2014 3:13 pm | News | Comments

AstraZeneca announced it has completed patient enrollment approximately four months ahead of plan in the Phase 3 clinical trial EUCLID studying Brilinta (ticagrelor) tablets. Read more...                 


Cirrhosis Drug Hits Primary Endpoints in Phase 3

March 17, 2014 2:52 pm | News | Comments

Intercept Pharmaceuticals Inc. announced that its international Phase 3 POISE trial of obeticholic acid (OCA) for the treatment of primary biliary cirrhosis (PBC) hit the primary endpoint of achieving a reduction in serum alkaline phosphatase. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.